Our proprietary CDK4/6 inhibitory compound narazaciclib was developed by in-house scientists with the goal of creating a more efficacious and safer compound to avoid the adverse events seen with other drugs in this class, such as marrow suppression, GI toxicity, and diffuse lung injury. Typically, these agents suppress the marrow and require a drug holiday to permit marrow cells to recover, which may also permit tumor cells to replicate during this time. Narazaciclib’s current clinical data provide the basis for its development for administration once daily and every day due to less marrow suppression.